Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice

<p> <br> </p> <p> <b>E.A.&nbsp;Abdulaeva<sup>1</sup>, E.L.&nbsp;Minkhuzina<sup>1,2</sup>,<sup> </sup>A.N.&nbsp;Kuskov<sup>2</sup></b> </p> <p> <b><sup>1</sup></b><...

Full description

Saved in:
Bibliographic Details
Main Authors: E.A. Abdulaeva, E.L. Minkhuzina, A.N. Kuskov
Format: Article
Language:Russian
Published: Prime-Media 2020-06-01
Series:РМЖ "Клиническая офтальмология"
Online Access:http://clinopht.com/upload/iblock/bb2/bb29917b5a48424f9a54887652366006.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841526776717639680
author E.A. Abdulaeva
E.L. Minkhuzina
A.N. Kuskov
author_facet E.A. Abdulaeva
E.L. Minkhuzina
A.N. Kuskov
author_sort E.A. Abdulaeva
collection DOAJ
description <p> <br> </p> <p> <b>E.A.&nbsp;Abdulaeva<sup>1</sup>, E.L.&nbsp;Minkhuzina<sup>1,2</sup>,<sup> </sup>A.N.&nbsp;Kuskov<sup>2</sup></b> </p> <p> <b><sup>1</sup></b><b>Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous </b><b>Professional Education, Kazan, Russian Federation</b> </p> <p> <b><sup>2</sup>Prof. E.V.&nbsp;Adamyuk Republician Clinical Ophthalmological Hospital, Kazan, Russian </b><b>Federation</b> </p> <p> <i>Diabetic retinopathy (DR) is a common microvascular complication of diabetes. As diabetes progresses, about 50% of patients with severe non-proliferative DR will develop proliferative DR (PDR) within one year. DR pathogenesis is mediated by alterations in many metabolic cascades, production of pro-inflammatory cytokines and growth factors, increased vascular leakage resulting from the loss of blood-retinal barrier integrity, and pathological neovascularization (which indicates increasing severity of DR). The introduction of anti-VEGF therapy has changed treatment paradigm for neovascularization as anti-VEGF agents target major pathophysiological mechanism of DR.&nbsp;Intensive studies on anti-VEGF therapy for PDR are now underway. This paper briefly reviews core studies on ranibizumab use in PDR and describes two case reports of PDR treatment with intravitreal injections of ranibizumab performed during one year according to prescribing information. Several clinical stud ies have demonstrated that anti-VEGF therapy is at least an alternative to panretinal photocoagulation in PDR.&nbsp;Our clinical observations confirm that ranibizumab is useful in routine clinical practice.</i> </p> <p> <i><b>Keywords</b>: proliferative diabetic retinopathy, diabetic macular edema, vascular endothelial growth factor, anti-VEGF.</i> </p> <p> <i><b>For citation: </b>Abdulaeva E.A., Minkhuzina E.L., Kuskov A.N. Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(2):97–103. DOI: 10.32364/2311-7729-2020-20-2-97-103.</i> </p>
format Article
id doaj-art-119391f0f0ac4abf84d35338fd8a4a6b
institution Kabale University
issn 2311-7729
2619-1571
language Russian
publishDate 2020-06-01
publisher Prime-Media
record_format Article
series РМЖ "Клиническая офтальмология"
spelling doaj-art-119391f0f0ac4abf84d35338fd8a4a6b2025-01-16T09:39:39ZrusPrime-MediaРМЖ "Клиническая офтальмология"2311-77292619-15712020-06-0120231106Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practiceE.A. Abdulaeva0E.L. Minkhuzina1A.N. Kuskov2Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> <br> </p> <p> <b>E.A.&nbsp;Abdulaeva<sup>1</sup>, E.L.&nbsp;Minkhuzina<sup>1,2</sup>,<sup> </sup>A.N.&nbsp;Kuskov<sup>2</sup></b> </p> <p> <b><sup>1</sup></b><b>Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous </b><b>Professional Education, Kazan, Russian Federation</b> </p> <p> <b><sup>2</sup>Prof. E.V.&nbsp;Adamyuk Republician Clinical Ophthalmological Hospital, Kazan, Russian </b><b>Federation</b> </p> <p> <i>Diabetic retinopathy (DR) is a common microvascular complication of diabetes. As diabetes progresses, about 50% of patients with severe non-proliferative DR will develop proliferative DR (PDR) within one year. DR pathogenesis is mediated by alterations in many metabolic cascades, production of pro-inflammatory cytokines and growth factors, increased vascular leakage resulting from the loss of blood-retinal barrier integrity, and pathological neovascularization (which indicates increasing severity of DR). The introduction of anti-VEGF therapy has changed treatment paradigm for neovascularization as anti-VEGF agents target major pathophysiological mechanism of DR.&nbsp;Intensive studies on anti-VEGF therapy for PDR are now underway. This paper briefly reviews core studies on ranibizumab use in PDR and describes two case reports of PDR treatment with intravitreal injections of ranibizumab performed during one year according to prescribing information. Several clinical stud ies have demonstrated that anti-VEGF therapy is at least an alternative to panretinal photocoagulation in PDR.&nbsp;Our clinical observations confirm that ranibizumab is useful in routine clinical practice.</i> </p> <p> <i><b>Keywords</b>: proliferative diabetic retinopathy, diabetic macular edema, vascular endothelial growth factor, anti-VEGF.</i> </p> <p> <i><b>For citation: </b>Abdulaeva E.A., Minkhuzina E.L., Kuskov A.N. Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(2):97–103. DOI: 10.32364/2311-7729-2020-20-2-97-103.</i> </p>http://clinopht.com/upload/iblock/bb2/bb29917b5a48424f9a54887652366006.pdf
spellingShingle E.A. Abdulaeva
E.L. Minkhuzina
A.N. Kuskov
Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
РМЖ "Клиническая офтальмология"
title Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
title_full Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
title_fullStr Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
title_full_unstemmed Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
title_short Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
title_sort anti vegf therapy for proliferative diabetic retinopathy translating research evidence into clinical practice
url http://clinopht.com/upload/iblock/bb2/bb29917b5a48424f9a54887652366006.pdf
work_keys_str_mv AT eaabdulaeva antivegftherapyforproliferativediabeticretinopathytranslatingresearchevidenceintoclinicalpractice
AT elminkhuzina antivegftherapyforproliferativediabeticretinopathytranslatingresearchevidenceintoclinicalpractice
AT ankuskov antivegftherapyforproliferativediabeticretinopathytranslatingresearchevidenceintoclinicalpractice